Puma Biotechnology Inc expected to post a loss of 2 cents a share - Earnings Preview

Puma Biotechnology

06/05/2025 23:58

Puma Biotechnology Inc PBYI.OQ PBYI.O is expected to show a rise in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

The Los Angeles California-based  company is expected to report a 1.7% increase in revenue to $44.55 million from $43.8 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Puma Biotechnology Inc is for a loss of 2 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 20.8% in the last three months. ​

Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.50​, above​ its last closing price of $2.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.11
0.10
0.39
Beat
279.9
Sep. 30 2024
0.34
0.35
0.41
Beat
16.9
Jun. 30 2024
-0.13
-0.13
-0.09
Beat
30.6​
Mar. 31 2024
-0.22
-0.22
-0.10
Beat
53.8
​​Dec. 31 2023
0.32
0.30
0.26
Missed
-13.2
Sep. 30 2023
0.08
0.08
0.12
Beat
56.5​
Jun. 30 2023
0.01
0.01
0.05
Beat
566.7
Mar. 31 2023
-0.07
-0.07
0.03
Beat
142.9

This summary was machine generated May 6 at 22:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)